Regenxbio RGNX Cash Paid For Interest Under Royalty Monetization Liabilities
Cash Paid For Interest Under Royalty Monetization Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:CashPaidForInterestUnderRoyaltyMonetizationLiabilities.
The official record: Regenxbio’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regenxbio's cash paid for interest under royalty monetization liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regenxbio's cash paid for interest under royalty monetization liabilities?
- Regenxbio (RGNX) reported cash paid for interest under royalty monetization liabilities of $8.03M in Q4 2025.
- How has Regenxbio's cash paid for interest under royalty monetization liabilities changed year-over-year?
- Regenxbio's cash paid for interest under royalty monetization liabilities increased by 389.5% year-over-year, from $1.64M to $8.03M.
- What does cash paid for interest under royalty monetization liabilities mean?
- This metric captures the cash interest expense incurred specifically on royalty-backed financing arrangements. It serves as a supplemental disclosure to clarify the cost of capital associated with monetizing future royalty rights. Investors use this to evaluate the true economic cost of debt servicing in complex biotech financing structures.